

# **AIRFORCEHEALTHSTUDY**

An Epidemiologic Investigation of  
Health Effects in Air Force Personnel  
Following Exposure to Herbicides

**SAIC Team**

**William D. Grubbs, Ph.D.**  
**Michael B. Lustik, M.S.**  
**Amy S. Brockman, M.S.**  
**Scott C. Henderson, M.S.**  
**Frank R. Burnett, M.S.**  
**Rebecca G. Land, M.S.**  
**Dawn J. Osborne, M.S.**  
**Vanessa K. Rocconi, B.S.**  
**Margaret E. Schrieber, B.A.**  
**David E. Williams, M.D., SCRF**

**Project Manager:** Manager E.B. Owens, Ph.D.  
**Statistical Task Manager:** W.D. Grubbs  
**SAIC Editor:** Jean M. Ault, B.A.

**Aii Force Team**

**Col William H. Wolfe, M.D., M.P.H.**  
**Joel E. Michalek, Ph.D.**  
**Col Judson C. Miner, D.V.M., M.P.H.**  
**Col Gary L. Heuriksen, M.D., M.P.H.**  
**Lt Col James A. Swaby, Ph.D., B.C.E.**

**Program Manager:** R.W. Ogershok

SCIENCE APPLICATIONS INTERNATIONAL  
1710 **Goodridge** Drive  
**McLean, Virginia** 22102

**EPIDEMIOLOGIC RESEARCH DIVISION**  
**ARMSTRONG LABORATORY**  
**HUMAN SYSTEMS CENTER (AFMC)**  
**BROOKS AIR FORCE BASE, TEXAS 78235**

**in conjunction with:**

SCRIPPS CLINIC & RESEARCH FOUNDATION,  
LA JOLLA, CALIFORNIA

NATIONAL OPINION RESEARCH CENTER,  
CHICAGO, ILLINOIS

**2 May 1995**

## **Volume III**

### **1992 Followup Examination Results**

May 1992 to May 1995

Contract Number F41624-91-C-1006  
SAIC Project Number 01-0813-02-3005

(Distribution Unlimited)

## AIR FORCE HEALTH STUDY

### An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides

May 1995

Volume III

1995 Followup Examination Results

Epidemiologic Research Division  
Armstrong Laboratory  
Human Systems Center (AFMC)  
Brooks Air Force Base, Texas 78235

## TABLE OF CONTENTS

### VOLUME III

	Page
<b>CHAPTER 12 PSYCHOLOGICAL ASSESSMENT . . . . .</b>	<b>12-1</b>
<b>INTRODUCTION . . . . .</b>	<b>12-1</b>
Background . . . . .	12-1
Summary of Previous Analyses of the Air Force Health Study . . . . .	12-3
1982 Baseline Study Summary Results . . . . .	12-3
1985 <b>Followup</b> Study Summary Results . . . . .	12-4
1987 <b>Followup</b> Study Summary Results . . . . .	12-5
Serum Dioxin Analysis of 1987 <b>Followup</b> Study Summary Results . . . . .	12-6
Parameters of the Psychological Assessment . . . . .	12-6
Dependent Variables . . . . .	12-6
Medical Records Data . . . . .	12-6
Physical Examination Data . . . . .	12-7
Covariates . . . . .	12-8
Statistical Methods . . . . .	12-8
<b>RESULTS.. . . . .</b>	<b>12-13</b>
Dependent Variable-Covariate Associations . . . . .	12-13
Exposure Analysis . . . . .	12-17
Verified Medical Records Variables . . . . .	12-18
Psychoses . . . . .	12-18
Alcohol Dependence . . . . .	12-18
Drug Dependence . . . . .	12-27
Anxiety.. . . . .	12-27
Other Neuroses . . . . .	12-36
Psychological Examination Variables . . . . .	12-41
SCL-90-R Anxiety . . . . .	12-41
SCL-90-R Depression . . . . .	12-46
SCL-90-R Hostility . . . . .	12-51
SCL-90-R Interpersonal Sensitivity . . . . .	12-56
SCL-90-R Obsessive-Compulsive Behavior . . . . .	12-61
SCL-90-R Paranoid Ideation . . . . .	12-66
SCL-90-R Phobic Anxiety . . . . .	12-71
SCL-90-R Psychoticism . . . . .	12-71
SCL-90-R Somatization . . . . .	12-80
SCL-90-R Global Severity Index . . . . .	12-85
SCL-90-R Positive Symptom Total . . . . .	12-90
SCL-90-R Positive Symptom Distress Index . . . . .	12-90
DISCUSSION . . . . .	12-99
<b>SUMMARY . . . . .</b>	<b>12-104</b>
Model 1: Group Analysis . . . . .	12-104
Model 2: Initial Dioxin Analysis . . . . .	12-104

TABLE OF CONTENTS (Continued)

	Page
Model 3: Categorized Dioxin Analysis .....	12-114
Models 4, 5, and 6: Current Dioxin Analyses .....	12-114
CONCLUSION .....	12-115
REFERENCES .....	..12-116

## LIST OF TABLES

	Page
Table 12-1. Statistical Analyses for the Psychological Assessment . . . . .	12-9
Table 12-2. Number of Participants with Missing Data for, or Excluded from, the Psychological Assessment . . . . .	12-14
Table 12-3. Analysis of Psychoses . . . . .	12-19
Table 12-4. Analysis of Alcohol Dependence . . . . .	12-23
Table 12-5. Analysis of Drug Dependence . . . . .	12-28
Table 12-6. Analysis of Anxiety . . . . .	12-32
Table 12-7. Analysis of Other Neuroses . . . . .	12-37
Table 12-8. Analysis of SCL-90-R Anxiety . . . . .	12-42
Table 12-9. Analysis of SCL-90-R Depression . . . . .	12-47
Table 12-10. Analysis of SCL-90-R Hostility . . . . .	12-52
Table 12-11. Analysis of SCL-90-R Interpersonal Sensitivity . . . . .	12-57
Table 12-12. Analysis of SCL-90-R Obsessive-Compulsive Behavior . . . . .	12-62
Table 12-13. Analysis of SCL-90-R Paranoid Ideation . . . . .	12-67
Table 12-14. Analysis of SCL-90-R Phobic Anxiety . . . . .	12-72
Table 12-15. Analysis of SCL-90-R Psychoticism . . . . .	12-76
Table 12-16. Analysis of SCL-90-R Somatization . . . . .	12-81
Table 12-17. Analysis of SCL-90-R Global Severity Index . . . . .	12-86
Table 12-18. Analysis of SCL-90-R Positive Symptom Total . . . . .	12-91
Table 12-19. Analysis of SCL-90-R Positive Symptom Distress Index . . . . .	12-95
Table 12-20. Summary of Group Analyses (Model 1) for Psychology Variables (Ranch Hands vs Comparisons) . . . . .	12-105
Table 12-21. Summary of Initial Dioxin Analyses (Model 2) for Psychology Variables (Ranch Hands vs Comparisons) . . . . .	12-107
Table 12-22. Summary of Categorized Dioxin Analyses (Model 3) for Psychology Variables (Ranch Hands vs Comparisons) . . . . .	12-108
Table 12-23. Summary of Current Dioxin Analyses (Models r, 5, and 6) for Psychology Variables (Ranch Hands Only) . . . . .	12-110
Table 12-24. Summary of Group-by-Covariate and dioxin-by-Covariate Interactions from Adjusted Analyses of Psychology Variables . . . . .	12-112

## TABLE OF CONTENTS

	Page
<b>CHAPTER 13 GASTROINTESTINAL ASSESSMENT .....</b>	<b>13-1</b>
<b>INTRODUCTION .....</b>	<b>13-1</b>
Background .....	13-1
Summary of Previous Analyses of the Air Force Health Study .....	13-2
1982 Baseline Study Summary Results .....	13-2
1985 Followup Study Summary Results .....	13-3
1987 Followup Study Summary Results .....	13-3
Serum Dioxin Analysis of 1987 Followup Study Summary Results .....	13-4
Parameters for the Gastrointestinal Assessment .....	13-4
Dependent Variables .....	13-4
Medical Records Data .....	13-4
Physical Examination Data .....	13-5
Laboratory Examination Data .....	13-5
Covariates .....	13-6
Statistical Methods .....	13-7
Longitudinal Analysis .....	13-17
<b>RESULTS .....</b>	<b>13-17</b>
Dependent Variable-Covariate Associations .....	13-17
Age .....	13-17
Race .....	13-18
Occupation .....	13-18
Industrial Chemical Exposure .....	13-19
Degreasing Chemical Exposure .....	13-19
Current Alcohol Use .....	13-19
Lifetime Alcohol History .....	13-20
Current Wine Use .....	13-20
Lifetime Wine History .....	13-20
Exposure Analysis .....	13-20
Verified Medical Records Variables .....	13-22
Hepatitis (non-A, Non-B, and Non-C) .....	13-22
Jaundice (Unspecified) .....	13-22
Acute and Subacute Necrosis of the Liver .....	13-31
Alcoholic Chronic Liver Disease and Cirrhosis .....	13-31
Nonalcoholic Chronic Liver Disease and Cirrhosis .....	13-38
Liver Abscess and Sequelae of Chronic Liver Disease .....	13-43
Other Liver Disorders .....	13-43
Hepatomegaly .....	13-50
Physical Examination Variable .....	13-55
Current Hepatomegaly .....	13-55
Laboratory Examination Variables .....	13-60
AST (Continuous) .....	13-60

## TABLE OF CONTENTS (Continued)

	Page
AST (Discrete) . . . . .	13-65
<b>ALT (Continuous) . . . . .</b>	<b>13-70</b>
ALT (Discrete) . . . . .	13-75
GGT (Continuous) . . . . .	13-80
GGT (Discrete) . . . . .	13-85
Alkaline Phosphatase (Continuous) . . . . .	13-90
Alkaline Phosphatase (Discrete) . . . . .	13-95
Total Bilirubin (Continuous) . . . . .	13-101
Total Bilirubin (Discrete) . . . . .	13-101
Direct Bilirubin . . . . .	13-110
LDH (Continuous) . . . . .	13-115
LDH (Discrete) . . . . .	13-120
Cholesterol (Continuous) . . . . .	13-125
Cholesterol (Discrete) . . . . .	13-130
HDL Cholesterol (Continuous) . . . . .	13-135
HDL Cholesterol (Discrete) . . . . .	13-141
Cholesterol-HDL Ratio (Continuous) . . . . .	13-146
Cholesterol-HDL Ratio (Discrete) . . . . .	13-151
Triglycerides (Continuous) . . . . .	13-156
Triglycerides (Discrete) . . . . .	13-161
Creatine Kinase (Continuous) . . . . .	13-162
Creatine Kinase (Discrete) . . . . .	13-171
Serum Amylase (Continuous) . . . . .	13-176
Serum Amylase (Discrete) . . . . .	13-181
Antibodies for Hepatitis A . . . . .	13-186
Serological Evidence of Present or Prior Hepatitis B Infection . . . . .	13-191
Antibodies for Hepatitis C . . . . .	13-196
Stool Hemoccult . . . . .	13-201
Prealbumin (Continuous) . . . . .	13-206
Prealbumin (Discrete) . . . . .	13-211
Albumin (Continuous) . . . . .	13-211
Albumin (Discrete) . . . . .	13-220
$\alpha$ -1 Acid Glycoprotein (Continuous) . . . . .	13-225
$\alpha$ -1 Acid Glycoprotein (Discrete) . . . . .	13-230
$\alpha$ -1 Antitrypsin (Continuous) . . . . .	13-235
$\alpha$ -1 antitrypsin (Discrete) . . . . .	13-241
$\alpha$ -2 Macroglobulin (Continuous) . . . . .	13-247
$\alpha$ -2 Macroglobulin (Discrete) . . . . .	13-252
Apolipoprotein B (Continuous) . . . . .	13-252
Apolipoprotein B (Discrete) . . . . .	13-261
$C_3$ Complement (Continuous) . . . . .	13-266
$C_3$ Complement (Discrete) . . . . .	13-271

## TABLE OF CONTENTS (Continued)

	Page
<b>C<sub>4</sub> Complement (Continuous) . . . . .</b>	13-276
<b>C<sub>4</sub> Complement (Discrete) . . . . .</b>	13-282
Haptoglobin (Continuous) . . . . .	13-282
Haptoglobin (Discrete) . . . . .	13-291
Transferrin (Continuous) . . . . .	13-296
Transferrin (Discrete) . . . . .	13-301
<b>Longitudinal Analysis . . . . .</b>	13-307
<b>Laboratory Examination Variables . . . . .</b>	13-308
AST (Continuous) . . . . .	13-308
AST (Discrete) . . . . .	13-308
ALT (Continuous) . . . . .	13-308
ALT (Discrete) . . . . .	13-308
GGT (Continuous) . . . . .	13-321
GGT (Discrete) . . . . .	13-321
Cholesterol (Continuous) . . . . .	13-328
Cholesterol (Discrete) . . . . .	13-328
HDL Cholesterol (Continuous) . . . . .	13-328
HDL Cholesterol (Discrete) . . . . .	13-338
Cholesterol-HDL Ratio (Continuous) . . . . .	13-338
Cholesterol-HDL Ratio (Discrete) . . . . .	13-338
Triglycerides (Continuous) . . . . .	13-338
Tryglycerides (Discrete) . . . . .	13-351
<b>DISCUSSION . . . . .</b>	13-351
<b>SUMMARY . . . . .</b>	13-357
<b>Medical Records . . . . .</b>	13-379
Model 1: Group Analysis . . . . .	13-379
Model 2: Initial Dioxin Analysis . . . . .	13-379
Model 3: Categorized Dioxin Analysis . . . . .	13-379
Models 4 through 6: Current Dioxin Analysis . . . . .	13-380
<b>Physical Examination Variable . . . . .</b>	13-380
<b>Laboratory Variables . . . . .</b>	13-380
<b>Model 1: Group Analysis . . . . .</b>	13-380
<b>Model 2: Initial Dioxin Analysis . . . . .</b>	13-381
<b>Model 3: Categorized Dioxin Analysis . . . . .</b>	13-381
<b>Models 4 through 6: Current Dioxin Analysis . . . . .</b>	13-382
<b>Overall . . . . .</b>	13-383
<b>CONCLUSION . . . . .</b>	13-384
<b>REFERENCES . . . . .</b>	13-385

## LIST OF TABLES

	Page
Table 13-1. Statistical Analyses for the Gastrointestinal Assessment . . . . .	13-8
Table 13-2. Number of Participants with Missing Data for, or Excluded from, the Gastrointestinal Assessment . . . . .	13-14
Table 13-3. Analysis of Hepatitis (Non-A, Non-B, and Non-C) . . . . .	13-23
Table 13-4. Analysis of Jaundice . . . . .	13-27
Table 13-5. Acute and Subacute Necrosis of the Liver . . . . .	13-32
Table 13-6. Analysis of Alcoholic Chronic Liver Disease and Cirrhosis . . . . .	13-34
Table 13-7. Analysis of Nonalcoholic Chronic Liver Disease and Cirrhosis . . . . .	13-39
Table 13-8. Liver Abscess and sequelae of Chronic Liver Disease . . . . .	13-44
Table 13-9. Analysis of Other Liver Disorders . . . . .	13-46
Table 13-10. Analysis of Hepatomegaly . . . . .	13-51
Table 13-11. Analysis of Current Hepatomegaly . . . . .	13-56
Table 13-12. Analysis of AST (U/L) (Continuous) . . . . .	13-61
Table 13-13. Analysis of AST (Discrete) . . . . .	13-66
Table 13-14. Analysis of ALT (U/L) (Continuous) . . . . .	13-71
Table 13-15. Analysis of ALT (Discrete) . . . . .	13-76
Table 13-16. Analysis of GGT (U/L) (Continuous) . . . . .	13-81
Table 13-17. Analysis of GGT (Discrete) . . . . .	13-86
Table 13-18. Analysis of Alkaline Phosphatase (U/L) (Continuous) . . . . .	13-91
Table 13-19. Analysis of Alkaline Phosphatase (Discrete) . . . . .	13-96
Table 13-20. Analysis of Total Bilirubin (mg/dl) (Continuous) . . . . .	13-102
Table 13-21. Analysis of Total Bilirubin (Discrete) . . . . .	13-106
Table 13-22. Analysis of Direct Bilirubin . . . . .	13-111
Table 13-23. Analysis of LDH (U/L) (Continuous) . . . . .	13-116
Table 13-24. Analysis of LDH (Discrete) . . . . .	13-121
Table 13-25. Analysis of Cholesterol (mg/dl) (Continuous) . . . . .	13-126
Table 13-26. Analysis of Cholesterol (Discrete) . . . . .	13-131
Table 13-27. Analysis of HDL Cholesterol (mg/dl) (Continuous) . . . . .	13-136
Table 13-28. Analysis of HDL Cholesterol (Discrete) . . . . .	13-142
Table 13-29. Analysis of Cholesterol-HDL Ratio (Continuous) . . . . .	13-147
Table 13-30. Analysis of Cholesterol-HDL Ratio (Discrete) . . . . .	13-152
Table 13-31. Analysis of Triglycerides (mg/dl) (Continuous) . . . . .	13-157
Table 13-32. Analysis of Triglycerides (Discrete) . . . . .	13-163
Table 13-33. Analysis of Creatine Kinase (U/L) (Continuous) . . . . .	13-167
Table 13-34. Analysis of Creatine Kinase (Discrete) . . . . .	13-172
Table 13-35. Analysis of Serum Amylase (U/L) (Continuous) . . . . .	13-177
Table 13-36. Analysis of Serum Amylase (Discrete) . . . . .	13-182
Table 13-37. Analysis of Antibodies for Hepatitis A . . . . .	13-187
Table 13-38. Analysis of Serological Evidence of Present or Prior Hepatitis B Infection . . . . .	13-192
Table 13-39. Analysis of Antibodies for Hepatitis C . . . . .	13-197
Table 13-40. Analysis of Stool Hemoccult . . . . .	13-202
Table 13-41. Analysis of Prealbumin (mg/dl) (Continuous) . . . . .	13-207
Table 13-42. Analysis of Prealbumin (Discrete) . . . . .	13-212

## LIST OF TABLES (Continued)

	Page
Table 13-43. Analysis of Albumin (mg.dl) (Continuous) .....	13-216
Table 13-44. Analysis of Albumin (Discrete) .....	13-221
Table 13-45. Analysis of $\alpha$ -1 Acid Glycoprotein (mg/dl) (Continuous) .....	13-226
Table 13-46. Analysis of $\alpha$ -1 Acid Glycoprotein (Discrete) .....	13-231
Table 13-47. Analysis of $\alpha$ -1 Antitrypsin (mg/dl) (Continuous) .....	12-236
Table 13-48. Analysis of $\alpha$ -1 Antitrypsin (Discrete) .....	13-242
Table 13-49. Analysis of $\alpha$ -2 Macroglobulin (mg/dl) (Continuous) .....	13-248
Table 13-50. Analysis of $\alpha$ -2 Macroglobulin (Discrete) .....	13-253
Table 13-51. Analysis of Apolipoprotein B(mg/dl) (Continuous) .....	13-257
Table 13-52. Analysis of Apolipoprotein B (Discrete) .....	13-262
Table 13-53. Analysis of $C_3$ Complement (mg/dl) (Continuous) .....	13-267
Table 13-54. Analysis of $C_3$ Complement (Discrete) .....	13-272
Table 13-55. Analysis of $C_4$ Complement (mg/dl) (Continuous) .....	13-277
Table 13-56. Analysis of $C_4$ Complement (Discrete) .....	13-283
Table 13-57. Analysis of Haptoglobin(mg/dl) (Continuous) .....	13-287
Table 13-58. Analysis of Haptoglobin (Discrete) .....	13-292
Table 13-59. Analysis of Transferrin (mg/dl) (Continuous) .....	13-297
Table 13-60. Analysis of Transferrin (Discrete) .....	13-302
Table 13-61. Longitudinal Analysis of AST(U/L) (Continuous) .....	13-309
Table 13-62. Longitudinal Analysis of AST (Discrete) .....	13-312
Table 13-63. Longitudinal Analysis of ALT (U/L) (Continuous) .....	13-315
Table 13-64. Longitudinal Analysis of ALT (Discrete) .....	13-318
Table 13-65. Longitudinal Analysis of GGT (U/L) (Continuous) .....	13-322
Table 13-66. Longitudinal Analysis of GGT (Discrete) .....	13-325
Table 13-67. Longitudinal Analysis of Cholesterol(mg/dl) (Continuous) .....	13-329
Table 13-68. Longitudinal Analysis of Cholesterol (Discrete) .....	13-332
Table 13-69. Longitudinal Analysis of HDL Cholesterol(mg/dl) (Continuous) .....	13-335
Table 13-70. Longitudinal Analysis of NDL Cholesterol (Discrete) .....	13-339
Table 13-71. Longitudinal Analysis of Cholesterol-HDL Ratio (Continuous) .....	13-342
Table 13-72. Longitudinal analysis of Cholesterol-HDL Ratio (Discrete) .....	13-345
Table 13-73. Longitudinal Analysis of triglycerides(mg/dl) (Continuous) .....	13-348
Table 13-74. Longitudinal Analysis of Triglycerides (Discrete) .....	13-352
Table 13-75. Summary of Group Analyses (Model 1) for Gastrointestinal Variables (Ranch Hands vs Comparisons) .....	13-358
Table 13-76. Summary of Initial Dioxin Analyses (Model 2) for Gastrointestinal Variables (Ranch Hands Only) .....	13-362
Table 13-77. Summary of Categorized Dioxin Analyses (Model 3) for Gastrointestinal Variables (Ranch Hands vs Comparisons) .....	13-364
Table 13-78. Summary of Current dioxin Analyses (Models 4, 5, and 6) for Gastrointestinal Variables (Ranch Hands Only) .....	13-369
Table 13-79. Summary of Group-by-Covariate and Dioxin-by-Covariate Interactions from Adjusted Analyses of Gastrointestinal Variables ..	13-373

## TABLE OF CONTENTS - REPORT

VOLUME I	EXECUTIVE SUMMARY ACKNOWLEDGEMENTS CHAPTER 1 - Introduction CHAPTER 2 - The Dioxin Assay CHAPTER 3 - Questionnaire Methodology CHAPTER 4 - Physical examination Methodology CHAPTER 5 - Study Selection and Participation CHAPTER 6 - Quality Control CHAPTER 7 - Statistical Methods CHAPTER 8 - Covariate Associations with Estimates of Dioxin Exposure CHAPTER 9 - General Health Assessment
VOLUME II	CHAPTER 10 - Neoplasia Assessment CHAPTER 11 - Neurological Assessment
VOLUME III	CHAPTER 12 - Psychological Assessment CHAPTER 13 - Gastrointestinal Assessment
VOLUME IV	CHAPTER 14 - Dermatologic Assessment CHAPTER 15 - Cardiovascular Assessment CHAPTER 16 - Hematologic Assessment
VOLUME V	CHAPTER 17 - Renal Assessment CHAPTER 18 - Endocrine Assessment
VOLUME VI	CHAPTER 19 - Immunologic Assessment CHAPTER 20 - Pulmonary Assessment CHAPTER 21 - Conclusions CHAPTER 22 - Future Directions
VOLUME VII	APPENDIX A - 1 through F-2
VOLUME VIII	APPENDIX G - 1 through I-4
VOLUME IX	APPENDIX J - 1 through N-4
VOLUME X	APPENDIX O - 1 through R